Updated 2026-08-13 · NCT07670884See eligibility →
Sponsor
Clinical trials sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.
Active studies whose public registry record names Fujian Shengdi Pharmaceutical Co., Ltd. as lead sponsor.
11active studies
6recruiting now
1countries represented
2largest site network
Current studies
Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.
Updated 2026-07-31 · NCT07559136See eligibility →
Updated 2026-01-26 · NCT06994650See eligibility →
Updated 2025-11-17 · NCT06934408See eligibility →
Updated 2025-11-17 · NCT06974851See eligibility →
Updated 2025-11-17 · NCT07150962See eligibility →
Updated 2026-09-08 · NCT07807059See eligibility →
Updated 2026-07-17 · NCT07709910See eligibility →
Opening soonPhase 2
A Study to Evaluate the Efficacy and Safety of HRS-4729 Injection in Obesity
Updated 2026-07-08 · NCT07690826See eligibility →
Active, not recruitingPhase 3
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
Updated 2026-02-27 · NCT07285902See eligibility →
Active, not recruitingPhase 2
HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
Updated 2025-11-24 · NCT06391710See eligibility →
Related sponsors
Novo Nordisk A/S71Eli Lilly and Company67University of Colorado, Denver36Cairo University31Mayo Clinic29Norwegian University of Science and Technology25
How current is this page?
The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.
Does appearing here mean I qualify?
No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.